Castle Biosciences (CSTL) Depreciation and Depletion (2018 - 2026)

Castle Biosciences has disclosed Depreciation and Depletion across 9 years of filings, most recently posting $1.7 million for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $1.7 million, up 18.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (up 18.33% YoY), and the FY2025 annual result was $5.9 million, up 21.3% from the prior year.
• Depreciation and Depletion came in at $1.7 million for Q1 2026 at Castle Biosciences, up from $1.5 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $1.7 million in Q1 2026 to a low of $503000.0 in Q1 2022.
• The 5-year median for Depreciation and Depletion is $1.1 million (2024), against an average of $1.1 million.
• Across the five-year window, Depreciation and Depletion surged 115.88% in 2022 and advanced 5.11% in 2025, its largest moves.
• Castle Biosciences' Depreciation and Depletion stood at $627000.0 in 2022, then surged by 51.99% to $953000.0 in 2023, then soared by 49.84% to $1.4 million in 2024, then grew by 5.11% to $1.5 million in 2025, then advanced by 13.46% to $1.7 million in 2026.
• The last three Depreciation and Depletion figures came in at $1.7 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.